Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

BioLineRx and I-Bridge Capital establish drug development JV in China BioLineRx has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China.
Drug Research > Drug Discovery & Development > News
F-star, Denali Therapeutics partner to develop multispecific antibody platform By PBR Staff Writer
UK-based biopharmaceutical firm F-star has signed a collaborative agreement with the US start-up Denali Therapeutics to develop a multispecific antibody platform for delivering therapeutics across the blood-brain barrier into the central nervous system (CNS).
Drug Research > Drug Discovery & Development > News Pfizer to acquire Medivation for $14bn By PBR Staff Writer
Pfizer has agreed to acquire US biopharmaceutical firm Medivation in a transaction valued at about $14bn.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Pfizer to acquire Medivation for $14bn
By PBR Staff Writer
Pfizer has agreed to acquire US biopharmaceutical firm Medivation in a transaction valued at about $14bn.
Drug Research > Drug Discovery & Development > News
DS Biopharma launches spin-out firm focused on fibrotic conditions and pulmonary disorders
DS Biopharma has launched a spin-out company focused solely on fibrotic conditions such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders such as chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF).
Drug Research > Drug Discovery & Development > News
Hemispherx Biopharma forms scientific advisory board to advice on drug development programs
Hemispherx Biopharma has formed a scientific advisory board (SAB) to leverage its member’s scientific and pharmaceutical expertise and advice to advance the Company’s drug development programs by providing guidance on steering the company forward and capitalizing on business opportunities as well as interactions with the Food and Drug Administration.
Drug Research > Drug Discovery & Development > News
Bayer and CRISPR Therapeutics JV starts operations in Massachusetts, US
By PBR Staff Writer
Casebia Therapeutics, the joint venture (JV) between Bayer and gene editing company CRISPR Therapeutics, has commenced its operations in Cambridge, Massachusetts, US.
Drug Research > Drug Discovery & Development > News
Xenetic Biosciences partners with Excivion to develop novel combined Zika and Dengue vaccine
Xenetic Biosciences has commenced a collaboration with Excivion to develop a vaccine against Zika and dengue viruses.
Drug Research > Drug Discovery & Development > News
Caribou Biosciences develops new method to profile CRISPR-Cas9 gene editing outcomes
Caribou Biosciences announced that members of its scientific team have discovered that DNA repair outcomes following Cas9 cleavage of DNA are nonrandom and follow highly reproducible patterns for each target site.
Drug Research > Drug Discovery & Development > News
Study suggests Zika virus may damage adult brain
By PBR Staff Writer
A new study has indicated the Zika virus, which is known to affect unborn babies, may also damage adult brain cells.
Drug Research > Drug Discovery & Development > News
Tioma Therapeutics raises $86m to further develop antibody portfolio
By PBR Staff Writer
Tioma Therapeutics, a venture-stage biopharmaceutical firm focused on the development of anti-CD47 antibodies to treat solid and hematologic cancers, has raised $86m in Series A venture financing.
Drug Research > Drug Discovery & Development > News
NeuroVive Pharmaceutical completes 10% acquisition of Isomerase Therapeutics
NeuroVive Pharmaceutical has completed the second step in the previously announced partial acquisition of the British drug discovery and development company Isomerase Therapeutics.
Drug Research > Drug Discovery & Development > News
Arrowhead Pharmaceuticals closes $45m private offering
Arrowhead Pharmaceuticals (ARWR) has closed a previously announced private offering with a select group of investors that include Orbimed, RA Capital Management, Perceptive Advisors, RTW Investments and other institutional investors.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests